NASDAQ:CGTX Cognition Therapeutics Q2 2025 Earnings Results & Report $0.68 +0.00 (+0.52%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.70 +0.03 (+3.71%) As of 11/13/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cognition Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$0.11 versus the -$0.12 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeBefore Market OpensConference Call4:00 PM ET Cognition Therapeutics EPS ResultsActual EPS-$0.11Consensus EPS -$0.12Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCognition Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cognition Therapeutics Q2 2025 Earnings FAQ Did Cognition Therapeutics beat earnings estimates for Q2 2025? Cognition Therapeutics (NASDAQ:CGTX) reported earnings of -$0.11 per share for Q2 2025, beating the consensus estimate of -$0.12. The report was announced on Thursday, August 7, 2025. Cognition Therapeutics Earnings HeadlinesHC Wainwright Has Positive Opinion of CGTX FY2026 EarningsNovember 13 at 1:43 AM | americanbankingnews.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesNovember 12 at 3:28 AM | americanbankingnews.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading. | Traders Agency (Ad)Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare ConferenceNovember 9, 2026 | globenewswire.comCognition's Q3 Loss Declines To $4 Mln As Phase 3 For Zervimesine In Dementia Set To BeginNovember 7, 2026 | rttnews.comCognition outlines mid-2027 Phase III start in DLB and cash runway into Q4 2027November 6, 2026 | seekingalpha.comSee More Cognition Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email. Email Address About Cognition TherapeuticsCognition Therapeutics (NASDAQ:CGTX) is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative diseases and other disorders affecting the central nervous system and retina. The company’s lead drug candidate, CT1812 (zervimesine), is an oral small molecule designed to target the sigma-2 receptor complex and disrupt the effects of toxic amyloid-beta oligomers on brain cells. Cognition has studied CT1812 in clinical programs for Alzheimer’s disease and dementia with Lewy bodies, and has also investigated its potential in retinal disease. Cognition Therapeutics’ work centers on developing treatments intended to protect or restore neuronal function, with research programs spanning multiple diseases for which treatment options remain limited.View Cognition Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
